In a human immunodeficiency virus -infected subject, cytomegalovirus (CMV) isolated 9 months after the patient began oral ganciclovir prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol coding regions. At 1 year, retinitis developed, which progressed despite intravenous ganciclovir followed by foscarnet and then cidofovir. A subsequent buffy coat virus isolate was resistant to all three drugs and contained new mutations in UL97 and Pol. By individually transferring the observed mutations to laboratory strain AD169, it was shown that a mutation at codon 603 of UL97 conferred resistance to ganciclovir, a mutation at codon 412 of Pol conferred resistance to both ganciclovir and cidofovir, and a mutation at codon 802 of Pol conferred resistance to ganciclovir and foscarnet. This case illustrates the development of multidrug resistance during prolonged exposure to antiviral therapy for CMV and cross-resistance arising from point mutations in the CMV Pol gene. . In this study, analyses of UL97 and Pol were performed tion therapy was attempted with the combination of ganciclovir on serial CMV isolates from a single patient who received (10 mg/kg/day) and foscarnet (180 mg/kg/day), followed by maintenance therapy with the combination. At week 25, no improveprolonged anti-CMV therapy beginning with oral ganciclovir ment was noted, and the patient was given intravenous cidofovir prophylaxis. The mutations conferring the remarkable triplefor Ç5 weeks without complication, but by week 30 this therapy drug resistance that ultimately developed were investigated. had failed. Reinduction treatment with ganciclovir (15 mg/kg/day) and foscarnet (180 mg/kg/day) was begun at week 31. His vision
In immunocompromised hosts, cytomegalovirus (CMV) distently thereafter (figure 1). His CD4 cell count fell to 3/mL at ease frequently progresses despite ongoing antiviral therapy month 12. Thirteen months after the patient started oral ganwith ganciclovir, foscarnet, or cidofovir. When this occurs, ciclovir, retinitis was noted in the right eye, limited to zone II. He there is concern for the development of drug resistance, alhad missed Ç25% of his oral ganciclovir doses in the 2 months though treatment failure may also result from other host-or prior to diagnosis. Induction therapy with intravenous ganciclovir treatment-related factors. The relative frequency, clinical imwas started (10 mg/kg/day). Three weeks later, retinitis was deportance, and mechanisms of CMV drug resistance are topics tected in the contralateral eye, and therapy was switched to intraveof active current investigation [1] .
nous foscarnet (180 mg/kg/day). Disease progression was halted Certain mutations in the viral UL97 phosphotransferase and but relapsed when the patient began receiving maintenance foscarthe DNA polymerase (Pol) genes result in CMV drug resistance net within 30 days of completion of the induction course. Reinduc- [1] . In this study, analyses of UL97 and Pol were performed tion therapy was attempted with the combination of ganciclovir on serial CMV isolates from a single patient who received (10 mg/kg/day) and foscarnet (180 mg/kg/day), followed by maintenance therapy with the combination. At week 25, no improveprolonged anti-CMV therapy beginning with oral ganciclovir ment was noted, and the patient was given intravenous cidofovir prophylaxis. The mutations conferring the remarkable triplefor Ç5 weeks without complication, but by week 30 this therapy drug resistance that ultimately developed were investigated. had failed. Reinduction treatment with ganciclovir (15 mg/kg/day) and foscarnet (180 mg/kg/day) was begun at week 31. His vision
Materials and Methods
and overall clinical condition continued to deteriorate despite this therapy. Intravitreal foscarnet (2.4 mg) was administered to both Case report. A 42-year-old human immunodeficiency virus eyes at week 41. His condition worsened, and he died at home 42 (HIV)-infected subject, with a CD4 cell count of 41/mL but no weeks after the initial diagnosis of CMV retinitis. A buffy coat history of AIDS-defining opportunistic infections, was enrolled in CMV isolate from late in the clinical course ( figure 1 ) was exama study of oral ganciclovir (1 g three times daily) for prevention ined for drug susceptibility and genetic characteristics. of CMV disease. Initially there was no overt CMV disease, and Virus isolates and susceptibility testing. Laboratory CMV an ophthalmologic examination was negative for retinitis. Study strain AD169 (American Type Culture Collection, Rockville, MD) drug was twice interrupted because of neutropenia (months 2 and was used as a control. CMV susceptibility testing to ganciclovir, foscarnet, and cidofovir was done by plaque reduction in cell cultures [2] . The IC 50 was determined. The IC 50 cutoff used to define resistance was 6 mM for ganciclovir, 400 mM for foscarnet, Figure 1 . Serial observations of CMV shedding, drug susceptibility, and resistance mutations during therapy.
amplified templates representing overlapping regions of the reThe Phe-to-Cys mutation at codon 412 of Pol (C412) was transferred by an infection-transfection procedure. Infectious AD169 spective coding regions. Templates were sequenced by use of a fluorescent dye terminator sequencing kit (AmpliTaq FS; Perkinextracellular virus (7 1 10 4 pfu) was ultracentrifuged, and the pelleted virus was mixed with 12 mL of the transfection reagent Elmer ABI, Foster City, CA) and the ABI 373A sequencer. Sequencing reactions used multiple sequencing primers representing (Lipofectamine; Life Technologies GIBCO-BRL, Gaithersburg, MD) and the DNA fragment containing the mutation to be transboth DNA strands to be sequenced and internal to the primers used to prepare templates [3, 4] . Sequence data were aligned with ferred (2 mg in 50 mL of serum-free medium). The 1.1-kb DNA fragment was PCR-amplified from the clinical isolate with the existing UL97 and Pol sequences, and all apparent deviations from reference sequences were confirmed by repeated sequencing reacprimer pair Pol1214 (5-CGCCGTGTCTGTCACGCCG-3) and Pol2316 (5-TGGTGTTGAACAGATCGCGCA-3). After incutions covering the same codons. Mutations in UL97 and Pol were defined as sequence changes from reference strains AD169 and bation at room temperature for 30 min, the mixture was diluted with 0.8 mL of serum-free medium and inoculated onto subconTowne (sequences available in Genbank) or other known drugsusceptible clinical isolates in the existing database [1, [3] [4] [5] [6] . fluent human fibroblast cultures. Growth medium without drug was replaced after 1 h. After 1 week, the cells were passed to a Marker transfer experiments. The UL97 and Pol mutations identified in the multiresistant late clinical isolate (figure 1) were fresh subconfluent monolayer of fibroblasts and cultured for 1 week under 40 mM ganciclovir. Supernatant virus was then pasindividually transferred by homologous recombination to laboratory strain AD169. The Cys-to-Trp mutation at codon 603 of UL97 saged to fresh fibroblasts and cultured under 40 mM ganciclovir for 3 weeks, with weekly trypsinization of the cell monolayer. (W603) and the Leu-to-Met mutation at codon 802 of Pol (M802) were transferred by use of minor modifications of a method preSupernatant virus was plaqued under agarose with no added drug. From plaques testing positive for the C412 mutation, one was viously published [3] . The mutant DNA fragment was 1.0 kb in length and was prepared by PCR amplification from the clinical selected for two additional rounds of plaque purification without drug. isolate with primer pairs CPT1088 (5-ACGGTGCTCACGGTC-TGGAT-3) and CPT2096 (5-CGTCAAGGTCCTCCTCGCA-3)
Genetic characterization of the recombinants consisted of sequencing of the entire UL97 and Pol coding regions, and each for W603 and Pol2566 (5-CTATGTTTCAGATGTCGCCGC-3) and Pol3550 (5-CGTTTCTTGCAGATCATCAT-3) for M802.
recombinant was tested for susceptibility to ganciclovir, foscarnet, and cidofovir in parallel with the parent AD169 strain. Supernatant virus from the initial transfection was plaqued once under drug (20 mM ganciclovir for W603 and 250 mM foscarnet for M802). Plaques were picked 1-2 weeks later and screened for later buffy coat isolate obtained after prolonged drug treatment was highly resistant to ganciclovir and cidofovir and resistant to foscarnet as well ( figure 1 ).
Sequence analysis of clinical isolates. The complete UL97
AD169 that were present in the baseline drug-susceptible clinical isolate from this subject. These were the insertion of a Ser coding sequence of the baseline susceptible clinical isolate showed amino acid change from strain AD169 at only 3 codons codon at 884 and an Ala-to-Thr change at codon 885 (T885). The recombinant virus T490-5-2-1 had the UL97 amino acid (68, 131, and 244). The isolate at 9 months was identical in UL97 amino acid sequence to the baseline isolate except for sequence of strain AD169 except for the W603 mutation. The Pol sequence was identical to that of strain AD169. the presence of a mutation at codon 592 (TGC-to-GGC or Cys-to-Gly, G592) previously reported in another ganciclovirresistant clinical isolate [6] . The third isolate showed amino Discussion acid changes at codons 125 (Leu-to-Gln) and 469 (His-to-Tyr), both previously encountered by us in susceptible clinical isoThe evolution of this case was remarkable for several features. An initially susceptible virus became resistant after 9 lates, and at codon 603 (TGC-to-TGG or Cys-to-Trp, W603), not previously noted in susceptible clinical isolates. months of oral ganciclovir prophylaxis for CMV in an AIDS patient, with the virus developing cross-resistance to cidofovir. The complete Pol coding sequence of the baseline susceptible clinical isolate showed amino acid differences from strain This was followed by overt retinitis, which responded suboptimally to intravenous ganciclovir, foscarnet, and cidofovir. A AD169 only at codons 628 (Pro-to-Leu), 655 (Ser-to-Leu), 685 (Asn-to-Ser), 884 (Ser inserted), and 885 (Ala-to-Thr, T885).
later virus isolate had become resistant to all three antiviral drugs. The Pol sequence of the isolate at 9 months was identical to the baseline isolate except for a mutation at codon 412 (TTT-toMutations in the CMV UL97 phosphotransferase gene, specifically at codons 460, 520, or 591 -596, are observed in TGT or Phe-to-Cys, C412). The last isolate had a Pol sequence identical to that of the 9-month isolate, except that it also Ç90% of ganciclovir-resistant clinical CMV isolates, with mutations at codons 460, 594, and 595 being the most common contained a second mutation at codon 802 (CTG-to-ATG or Leu-to-Met, M802). [1, 3 -11] . In this case, we have shown experimentally that the W603 mutation also confers ganciclovir resistance. Some other Comparative analysis of sequences from the 3 clinical isolates suggested that the G592 and W603 mutations in UL97 mutations in the codon 597 -607 range may have a similar effect [1, 7] . Resistance to foscarnet or cidofovir is not expected each conferred ganciclovir resistance, the C412 mutation in Pol conferred at least cidofovir resistance, and the M802 mutato result from mutations in UL97, as illustrated by the W603 recombinant virus (table 1) . tion in Pol conferred at least foscarnet resistance. Because of a number of possible interpretations of the cross-resistance Information on the character and frequency of Pol resistance mutations in clinical CMV isolates is still limited [1, 4, 5, 7] . properties of the Pol mutations, each mutation observed in the last multiresistant isolate was separately transferred to laboraBecause of complexity introduced by interstrain variation and possible cross-resistance, marker transfer experiments, in tory strain AD169 to test its functional effect in isolation.
Analysis of recombinant viruses. Three recombinant viwhich putative resistance mutations are individually transferred to well-defined laboratory strains of CMV by homologous reruses were isolated and analyzed after three rounds of plaque purification. They had the mutations and susceptibility data combination, are important in determining the phenotypic correlates of specific Pol mutations. Earlier reports involving laboshown in table 1. All recombinant viruses appeared to grow and passage normally in cell culture. The recombinant virus ratory-derived CMV mutants indicated that dual ganciclovir and cidofovir resistance resulted from mutations at codons 987 T348-11-4-11 had a UL97 coding sequence identical to that of strain AD169 and a Pol coding sequence that contained the [12] , 501, and probably 412 [13] .
In clinical isolates, Pol mutations contribute to and occasion-C412 mutation but was otherwise identical to that of strain AD169. The recombinant virus T516-4-10-1 had a UL97 seally may be the sole basis for ganciclovir resistance [4] . Some mutations result in cross-resistance. For example, the C412 quence identical to that of strain AD169 and a Pol coding sequence that contained the M802 mutation. This recombinant mutation conferred resistance to both ganciclovir and cidofovir (table 1) in a subject who had not received cidofovir. Mutations also contained some other amino acid differences from strain / 9d31$$se29 07-24-97 11:56:02 jinfa UC: J Infect
